Edition:
United Kingdom

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.60EUR
23 Feb 2018
Change (% chg)

€-0.03 (-1.90%)
Prev Close
€1.63
Open
€1.63
Day's High
€1.63
Day's Low
€1.59
Volume
221,583
Avg. Vol
632,457
52-wk High
€5.46
52-wk Low
€0.98

Select another date:

Tue, Jan 23 2018

BRIEF-Onxeo Provides Update on Litigation with SpeBio/SpePharm

* ONXEO SA - SUBMITTED CONCLUSIONS TO PARIS COURT OF APPEAL CONCERNING MERITS OF LITIGATION AGAINST SPEPHARM/SPEBIO B.V COMPANIES

BRIEF-Onxeo reports commercial court of Paris decision in lawsuit against SpeBio/SpePharm​

* ‍Onxeo reports first instance decision from commercial court of Paris in lawsuit against SpeBio/SpePharm​

BRIEF-Onxeo introduces chemistry platform of decoy oligonucleotides platON

* ONXEO INTRODUCES PLATON™, A PROPRIETARY CHEMISTRY PLATFORM OF DECOY OLIGONUCLEOTIDES

BRIEF-Onxeo ‍announces preclinical data for combination of AsiDNA™ and belinostat​

* ‍ANNOUNCES COMPELLING PRECLINICAL DATA IN COMBINATION FOR ITS TWO INNOVATIVE COMPOUNDS, ASIDNA™ AND BELINOSTAT​

BRIEF-Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics

* ONXEO GRANTS EXCLUSIVE WORLDWIDE LICENSE OF VALIDIVE DEVELOPED FOR THE TREATMENT OF ORAL SEVERE MUCOSITIS TO MONOPAR THERAPEUTICS

BRIEF-Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced hepatocellular carcinoma

* Onxeo announces top-line results from ReLive Phase III study of Livatag® in advanced hepatocellular carcinoma

Select another date: